Drug Trial Radar · NCT06925061
Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Mar 31, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Madeleine BezaultAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MAINTAIN-POP is a Phase 2, randomised, double-blind, placebo-controlled, multicenter study of the impact of oral administration of EXL01 in the prevention of post-operative endoscopic recurrence of Crohn's disease after surgery. Approximately 80 eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeks or until a study or treatment discontinuation criterion is met. Randomisation will be stratified on post-surgical treatment (none vs anti-TNF), and on smoking status (non-smoker vs smoker). The primary objective is to compare the distribution of endoscopic modified Rutgeerts scores, as centrally assessed, at 6 months post-surgery in patients with CD treated with EXL01 to patients treated with placebo. Endoscopic recurrence will be assessed using the endoscopic score assessed by central reading at Week 24 after surgery. All participants will be followed for safety until 4 weeks after end of treatment.
Conditions
- Crohn Disease (CD)
Interventions
After surgery for Crohn's disease, eligible patients will be randomized 1:1 to receive oral EXL01 or placebo with or without SoC treatment (based on investigator decision) for up to 24 weeksDrug
Randomisation will be stratified on post-surgical treatment (none vs anti-TNF), and on smoking status (non-smoker vs smoker).
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare the distribution of endoscopic modified Rutgeerts scores, as centrally assessed, at 6 months post-surgery in patients with CD treated with EXL01 to patients treated with placebo.Time frame: From enrollment to the end of treatment at 24 weeks
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
CHU Clermont-Ferrand
Clermont-Ferrand, France · Recruiting
Hôpital Henri Mondor
Créteil, France · Recruiting
Hôpital Bicêtre
Le Kremlin-Bicêtre, France · Recruiting
CHU Lille
Lille, France · Recruiting
Hospices civils Lyon Sud
Lyon, France · Recruiting
CHU Marseille Nord
Marseille, France · Recruiting
CHU Montpellier
Montpellier, France · Recruiting
CHU Nancy
Nancy, France · Recruiting
CHU Nantes
Nantes, France · Recruiting
CHU Nice Archet 2
Nice, France · Recruiting
CHU Saint Louis
Paris, France · Recruiting
Hôpital Saint Antoine
Paris, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.